StockWatch
·
Q2 FY-2027 RESULTS · SHALBY

Shalby consolidated PAT up 8% YoY to ₹7.9 Cr as Medtech losses widen further

PAT +8.35% YoY · revenue +9.72% · margins compressing

Q2 FY27 resultsSHALBYShalby Ltd03 Nov 2026 · 3 min read
Revenue

₹313.17 Cr

+9.72% YoY

PAT (consolidated)

₹7.89 Cr

+8.35% YoY

Net margin

2.48%

0pp YoY

EPS

₹0.73

Shalby's consolidated revenue came in at ₹313.17 Cr (+9.7% YoY, -5.5% QoQ) and consolidated PAT at ₹7.89 Cr (+8.4% YoY, -24.9% QoQ) for Q2 FY27. No quarter-specific street estimate for Q2 FY27 could be located (trackers show only full-year FY27 consensus — EPS ₹4.20, +30% — with a near-unanimous Buy rating), so vs-street is unknown rather than graded.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹313.17 Cr-5.4%+9.7%
Expenses₹301.74 Cr-5.4%+11.4%
PAT₹7.89 Cr-24.87%+8.35%
Net margin2.48%-0.6pp0pp
EPS₹0.73-25.5%+7.4%

NPM was essentially flat YoY at 2.52% (vs 2.51%) but down sequentially from 3.10% in Q1 FY27; OPM came in at 13.22%, down from 14.58% a year ago though up from Q1's 12.56%. The Healthcare Services segment, the core of the business, grew PBT 9.8% YoY to ₹28.11 Cr on 12.1% revenue growth to ₹283.21 Cr — consistent with management's push toward the 20% hospital EBITDA margin target it set out for FY27 in the August 2026 concall, though no EBITDA breakout is disclosed to confirm the exact trajectory. Working against this, the Manufacturing & Trading of Implants (Medtech) segment's loss widened 78% YoY to ₹11.64 Cr on an 8.8% revenue decline to ₹29.97 Cr — the opposite of management's guidance that regulatory changes would bring Medtech to double-digit EBITDA margins within 6-9 months. The segment's deterioration coincides with Shalby Medtech CEO Deepak Anand's resignation on August 18, 2026, with no replacement named in this filing.

₹
105.75122.16138.57154.98171.39122.1307-3108-2409-1610-0911-03Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹122.13, down 8.6% over the past month of trading.

₹ Cr
06.8913.7820.677.68Q1 FY26rev ₹296 Cr7.28Q2 FY26rev ₹285 Cr13.79Q3 FY26rev ₹215 Cr18.45Q4 FY26rev ₹287 Cr10.5Q1 FY27rev ₹331 Cr7.89Q2 FY27rev ₹313 Cr
Quarterly consolidated PAT, ₹ Crore
What management guided (1 FY-2027 call)
Hospital EBITDA margin targeting upward to 20% for FY27. MedTech targeting double-digit EBITDA margins post-regulatory changes (6-9 months). ROCE expansion to 11-13% industry standard within 1-2 years via capex ROI and minimal further capex planned.

— This quarter: missed

No management press release accompanies this result, so there is no company framing to reconcile against the numbers. Standalone PAT of ₹23.50 Cr (EPS ₹2.19) is well above consolidated PAT of ₹7.89 Cr (EPS ₹0.73); the gap is entirely subsidiary-level losses, chiefly Medtech, consolidating down group profit. Both statements carry no exceptional items this quarter or a year ago, so YoY growth is on a clean base. Separately, the board approved appointing Shanay Vikram Shah and Tushar Shah as Whole-Time/Executive directors, subject to a shareholder postal ballot due December 5, 2026 — a governance move unconnected to this quarter's operating print.

  • W1

    Medtech segment EBITDA margin trajectory — management guided double-digit margins within 6-9 months of regulatory changes (Aug 2026 concall); segment loss was ₹11.64 Cr this quarter, widened from ₹6.52 Cr YoY

  • W2

    Hospital EBITDA margin progress toward management's 20% FY27 target — Healthcare segment PBT margin was ~9.9% this quarter

  • W3

    Jabalpur hospital fire disruption (registration suspended Oct 14, 2026; full operations resumed Oct 28, 2026) falls in Q3 FY27 — watch for revenue/margin impact in the next print

Source is in ₹ Million, converted to Crore (÷10). No exceptional items in current or year-ago quarter (both periods). Consolidated 'Profit for the period' (₹7.886 Cr, before NCI split) is used as netProfit, consistent with DB convention — this exact figure reconciles with the prior-quarter (₹10.496 Cr) and year-ago (₹7.278 Cr) DB values pulled from this same statement's columns. Tax figure derived as current tax + adjustment for earlier years + deferred tax (MAT credit nil this quarter).

Informational and educational content only. Not investment advice.